SEARCH

SEARCH BY CITATION

References

  • 1
    Holick MF, Vitamin D. importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004; 79: 362371.
  • 2
    Mosekilde L. Vitamin D and the elderly. Clin Endocrinol 2005; 62: 265281. Prosser DE, Jones G. Enzymes involved in the activation and inactivation ofvitamin D. Trends Biochem Sci 2004; 29: 664673.
  • 3
    Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer H, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726776.
  • 4
    Chiu KC, Chu A, Go V, Saad MF. Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am J Clin Nutr 2004; 79: 820825.
  • 5
    Heubi JE, Hollis BW, Specker B, Tsang RC. Bone disease in chronic childhood cholestasis. I: vitamin D absorption and metabolism. HEPATOLOGY 1989; 9: 258264.
  • 6
    Klein GL, Soriano H, Shulman RJ, Levy M, Jones G, Langman CB. Hepatic osteodystrophy in chronic cholestasis: evidence for a multifactorial etiology. Pediatr Transplant 2002; 6: 136140.
  • 7
    Schiefke I, Fach A, Wiedmann M, Aretin AV, Schenker E, Borte G, et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 2005; 11: 18431847.
  • 8
    Duarte M, Farias ML, Coelho HS, Mendoca L, Stabnov L, Oliveira M, et al. Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol 2001; 16, 10221027.
  • 9
    Chen CC, Wang SS, Jeng FS, Lee SD. Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol 1996; 11: 417421.
  • 10
    Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 2007; 5: 513520.
  • 11
    Monegal A, Navata M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 1997; 60: 148154.
  • 12
    Tsuneoka K, Tameda Y, Takase K, Nakano T. Osteodystrophy in patients with chronic hepatitis and liver cirrhosis. J Gastroenterol 1996; 31: 669678.
  • 13
    Bouillon R, Auwerx J, Dekeyser L, Fevery J, Lissens W, De Moor P. Serum vitamin D metabolites and their binding protein in patients with liver cirrhosis. J Clin Endocrinol Metab 1984; 59: 8689.
  • 14
    Masuda S, Okano T, Osawa K, Shinjo M, Suematsu T, Kobayashi T. Concentrations of vitamin D metabolites in plasma of patients with liver cirrhosis. J Nut Sci Vitaminol 1989; 35: 225234.
  • 15
    Hofmann WP, Kronenberger B, Bojunga J, Stamm B, Herrmann E, Bucker A, et al. Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon α and ribavirin therapy. J Viral Hepatitis 2008; 15: 790796.
  • 16
    Diamond TH, Stiel D, Lunzer M, McDowall D, Eckstein RP, Posen S. Hepatic osteodystrophy: static and dynamic bone hystomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease. Gastroenterology 1989; 96: 213221.
  • 17
    Bonkovsky HL, Hawkins M, Steinberg K, Hersh T, Galambos JT, Henderson JM, et al. Prevalence and prediction of osteopenia in chronic liver disease. HEPATOLOGY 1990; 12: 273280.
  • 18
    Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, Casado-Caballero F, Ruiz-Escolano E, Olivares EG. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab 2004; 89: 43254330.
  • 19
    Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007; 17: 517524.
  • 20
    American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. American Diabetes Association: Clinical Practice Recommendations 2000 Committee Report. Diabetes Care 2000; 23: S4S19.
  • 21
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412419.
  • 22
    Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239244.
  • 23
    Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991; 13: 372374.
  • 24
    EASL International Consensus Conference on Hepatitis C Paris. 26–27 February 1999 Consensus Statement. J Hepatol 1999; 31: S3S8.
  • 25
    Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361387.
  • 26
    Petta S, Camma C, Di Marco V, Alessi N, Cabibi D, Caldarella R, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008; 103: 11361144.
    Direct Link:
  • 27
    Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416423.
  • 28
    Vari IS, Balkau B, Kettaneh A, André P, Tichet J, Fumeron F, et al; DESIR Study Group. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2007; 30: 17951801.
  • 29
    Veldman C, Cantorna M, DeLuca H. Expression of 1, 25 dihydroxyvitamin D3 receptor in the immune system. Arch Biochem Biophys 2000; 374: 334338.
  • 30
    Willheim M, Thien R, Schrattbauer K, Bajna E, Holub M, Gruber R, et al. Regulatory effects of 1alpha, 25 dihydroxyvitamin D3 on the cytokine production of human peripheral blood lymphocytes. J Clin Endocrinol Metab 1999; 84: 37393744.
  • 31
    Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? Q J Med 2002; 95: 787796.
  • 32
    Cigolini M, Iagulli MP, Miconi V, Galiotto M, Lombardi S, Targher G. Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care 2006; 29: 722724.
  • 33
    Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004; 80(Suppl): 1717S1720S.
  • 34
    Abu-Mouch S, Fireman Z, Jarchovsky J, Assy N. The beneficial effect of vitamin D combined eg interferon and ribavirin for chronic HCV infection. HEPATOLOGY 2009; 50(Suppl.): LB20.
  • 35
    Camma C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. HEPATOLOGY 2006; 43: 6471.
  • 36
    Cammà C, Petta S. Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: looking to the future. J Hepatol 2009; 50: 648651.